5 Stocks Under $10 Set to Soar
Amicus Therapeutics
An under-$10 stock in the biotechnology and drugs complex that's trading very close to triggering a near-term breakout trade is Amicus Therapeutics (FOLD), which is focused on the discovery, development and commercialization of a new class of orally administered, small molecule drugs, for the treatment of a range of human genetic diseases. This stock has been on fire so far in 2012, with shares up a whopping 75%.
>>5 Stocks Poised to Pop on Bullish Earnings
If you take a look at the chart for Amicus Therapeutics, you'll notice that for the last two months, this stock has been uptrending from a low of $4.50 to its recent high of $6.15 a share. During that uptrend, shares of FOLD have been mostly making higher lows and higher highs, which is bullish technical price action. That move has now pushed FOLD within range of triggering a near-term breakout trade.
Traders should now look for long-biased trades in FOLD once it manages to break out above some near-term overhead resistance at $6.15 with high volume. Look for a sustained move or close above $6.15 with volume that hits near or above its three-month average action of 838,068 shares. If that breakout triggers soon, then FOLD will setup to re-test or possibly take out its next significant overhead resistance levels at $6.89 to $7.29 a share. If those levels get taken out with volume, then FOLD could easily trade north of $8 a share in the near future. Traders can look to buy FOLD off any weakness, and simply use a stop somewhere below its 200-day moving average of $5.31 a share. A better strategy might be to buy off strength once FOLD clears $6.15 a share with volume, and then use a stop just below $5.60 a share. I would look to add to either position once FOLD takes out $6.89 to $7.29 a share with heavy volume.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV